

# yves Dauvilliers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7508105/publications.pdf>

Version: 2024-02-01

393  
papers

23,350  
citations

7251

80  
h-index

15253

130  
g-index

438  
all docs

438  
docs citations

438  
times ranked

15801  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dreamâ€enactment behaviours during the <scp>COVID</scp>â€19 pandemic: an international <scp>COVID</scp>â€19 sleep study. <i>Journal of Sleep Research</i> , 2023, 32, .	1.7	10
2	Responsiveness of Daytime Sleepiness and Fatigue Scales in Myotonic Dystrophy Type 1. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 287-290.	0.3	1
3	Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 235-244.	1.4	5
4	Symptom network analysis of the sleep disorders diagnostic criteria based on the clinical text of the ICSIDâ€3. <i>Journal of Sleep Research</i> , 2022, 31, e13435.	1.7	5
5	Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. <i>Sleep</i> , 2022, 45, .	0.6	18
6	Evening-types show highest increase of sleep and mental health problems during the COVID-19 pandemicâ€”multinational study on 19 267 adults. <i>Sleep</i> , 2022, 45, .	0.6	42
7	Disrupted nighttime sleep and sleep instability in narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 289-304.	1.4	29
8	Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia. <i>Sleep</i> , 2022, 45, .	0.6	14
9	A series of 8 cases of sleep-related psychogenic dissociative disorders and proposed updated diagnostic criteria. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 563-573.	1.4	9
10	Histamine in murine narcolepsy: What do genetic and immune models tell us?. <i>Brain Pathology</i> , 2022, 32, e13027.	2.1	5
11	Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 617-629.	1.4	11
12	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. <i>Journal of Parkinson's Disease</i> , 2022, 12, 333-340.	1.5	3
13	<scp>THN</scp> 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. <i>Movement Disorders</i> , 2022, 37, 410-415.	2.2	6
14	Metabolomics Signature of Patients With Narcolepsy. <i>Neurology</i> , 2022, 98, .	1.5	15
15	Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy. <i>Brain</i> , 2022, 145, 2018-2030.	3.7	13
16	Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. <i>Lancet Neurology</i> , The, 2022, 21, 53-65.	4.9	37
17	Risk Factors for Phenoconversion in <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2022, 91, 404-416.	2.8	27
18	Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 1355-1364.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 12.	3.0	12
20	Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome. <i>Movement Disorders</i> , 2022, 37, 812-825.	2.2	9
21	Disturbances in sleep, circadian rhythms and daytime functioning in relation to coronavirus infection and Longâ€œCOVID â€œ A multinational ICOS study. <i>Journal of Sleep Research</i> , 2022, 31, e13542.	1.7	21
22	Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. <i>Nature and Science of Sleep</i> , 2022, Volume 14, 531-546.	1.4	3
23	Linking clinical complaints and objective measures of disrupted nighttime sleep in narcolepsy type 1. <i>Sleep</i> , 2022, 45, .	0.6	10
24	Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. <i>CNS Drugs</i> , 2022, 36, 377-387.	2.7	8
25	Narcolepsy with intermediate cerebrospinal level of hypocretin-1. <i>Sleep</i> , 2022, 45, .	0.6	14
26	Does the adenosine deaminase ( <i>ADA</i> ) gene confer risk of sleepwalking?. <i>Journal of Sleep Research</i> , 2022, 31, e13537.	1.7	4
27	Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering. <i>Neurology</i> , 2022, 98, .	1.5	17
28	0389 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale Score. <i>Sleep</i> , 2022, 45, A174-A175.	0.6	0
29	Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. <i>CNS Drugs</i> , 2022, 36, 633-647.	2.7	7
30	0387 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Idiopathic Hypersomnia. <i>Sleep</i> , 2022, 45, A173-A174.	0.6	1
31	0393 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Narcolepsy. <i>Sleep</i> , 2022, 45, A176-A176.	0.6	2
32	0390 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Idiopathic Hypersomnia Severity Scale Score. <i>Sleep</i> , 2022, 45, A175-A175.	0.6	0
33	Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 2217-2227.	1.4	7
34	The orexin story, sleep and sleep disturbances. <i>Journal of Sleep Research</i> , 2022, 31, .	1.7	24
35	Maintenance of wakefulness test: how does it predict accident risk in patients with sleep disorders?. <i>Sleep Medicine</i> , 2021, 77, 249-255.	0.8	26
36	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	2.7	46

#	ARTICLE	IF	CITATIONS
37	Comprehensive Analysis of Familial Parkinsonism Genes in Rapid Eye Movement Sleep Behavior Disorder. <i>Movement Disorders</i> , 2021, 36, 235-240.	2.2	11
38	Analysis of Heterozygous <i>PRKN</i> Variants and Copy Number Variations in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 178-187.	2.2	39
39	Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate) in narcolepsy with cataplexy. <i>Sleep</i> , 2021, 44, .	0.6	39
40	Characteristics associated with hypersomnia and excessive daytime sleepiness identified by extended polysomnography recording. <i>Sleep</i> , 2021, 44, .	0.6	21
41	Targeted sequencing of Parkinson's disease loci genes highlights <i>SYT11</i> , <i>FGF20</i> and other associations. <i>Brain</i> , 2021, 144, 462-472.	3.7	31
42	Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP. <i>Chest</i> , 2021, 159, 1598-1609.	0.4	46
43	Sleep-related head jerks: toward a new movement disorder. <i>Sleep</i> , 2021, 44, .	0.6	7
44	New 2013 incidence peak in childhood narcolepsy: more than vaccination?. <i>Sleep</i> , 2021, 44, .	0.6	11
45	Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence. <i>Sleep</i> , 2021, 44, .	0.6	15
46	Hypocretin/Orexin, Sleep and Alzheimer's Disease. <i>Frontiers of Neurology and Neuroscience</i> , 2021, 45, 139-149.	3.0	17
47	Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the <i>TRANK1</i> gene loci. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
48	Systematic assessment of autonomic symptoms in restless legs syndrome. <i>Sleep Medicine</i> , 2021, 80, 30-38.	0.8	6
49	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 100, 119.e7-119.e13.	1.5	19
50	The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: a population-based international harmonized study. <i>Sleep and Breathing</i> , 2021, 25, 849-860.	0.9	37
51	344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages. <i>Sleep</i> , 2021, 44, A137-A138.	0.6	1
52	490 Efficacy of FT218 on Polysomnographic Measures of Sleep Continuity in Patients With Narcolepsy: Results From the REST-ON Trial. <i>Sleep</i> , 2021, 44, A193-A194.	0.6	0
53	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. <i>Annals of Neurology</i> , 2021, 90, 62-75.	2.8	73
54	485 Efficacy and Safety of Once- and Twice-Nightly Dosing of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia. <i>Sleep</i> , 2021, 44, A191-A192.	0.6	1

#	ARTICLE	IF	CITATIONS
55	487 Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal Study. <i>Sleep</i> , 2021, 44, A192-A192.	0.6	0
56	489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results. <i>Sleep</i> , 2021, 44, A193-A193.	0.6	2
57	495 Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured by the Idiopathic Hypersomnia Severity Scale. <i>Sleep</i> , 2021, 44, A195-A195.	0.6	0
58	488 REST-ON: Efficacy of FT218 for Daytime Sleepiness, Sleep Quality, Hallucinations, and Sleep Paralysis in Patients With Narcolepsy. <i>Sleep</i> , 2021, 44, A192-A193.	0.6	0
59	500 Correlation of the Idiopathic Hypersomnia Severity Scale With Other Measures of Sleep Parameters in a Phase 3 Trial. <i>Sleep</i> , 2021, 44, A197-A197.	0.6	1
60	494 Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia. <i>Sleep</i> , 2021, 44, A195-A195.	0.6	1
61	Measurement of Narcolepsy Symptoms in School-Aged Children and Adolescents. <i>Neurology</i> , 2021, 97, e476-e488.	1.5	18
62	2018 worldwide survey of health-care providers caring for patients with narcolepsy. <i>Sleep Medicine</i> , 2021, 82, 23-28.	0.8	4
63	European guideline and expert statements on the management of narcolepsy in adults and children. <i>European Journal of Neurology</i> , 2021, 28, 2815-2830.	1.7	67
64	Self-perceived sleep during the Maintenance of Wakefulness Test: how does it predict accidental risk in patients with sleep disorders?. <i>Sleep</i> , 2021, 44, .	0.6	6
65	European guideline and expert statements on the management of narcolepsy in adults and children. <i>Journal of Sleep Research</i> , 2021, 30, e13387.	1.7	44
66	A systematic analysis of ICSD-3 diagnostic criteria and proposal for further structured iteration. <i>Sleep Medicine Reviews</i> , 2021, 58, 101439.	3.8	24
67	Identifying the best biomarkers for $\alpha$ -synucleinopathies. <i>Lancet Neurology</i> , The, 2021, 20, 593-594.	4.9	3
68	Cardiovascular disorders in narcolepsy: Review of associations and determinants. <i>Sleep Medicine Reviews</i> , 2021, 58, 101440.	3.8	39
69	How our Dreams Changed During the COVID-19 Pandemic: Effects and Correlates of Dream Recall Frequency - a Multinational Study on 19,355 Adults. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1573-1591.	1.4	30
70	Insomnia, anxiety, and depression during the COVID-19 pandemic: an international collaborative study. <i>Sleep Medicine</i> , 2021, 87, 38-45.	0.8	177
71	Narcolepsy, Idiopathic Hypersomnia, and Dysautonomia. , 2021, , 187-198.		1
72	Novel Associations of <i>BST1</i> and <i>LAMP3</i> With REM Sleep Behavior Disorder. <i>Neurology</i> , 2021, 96, e1402-e1412.	1.5	12

#	ARTICLE	IF	CITATIONS
73	Video-Polysomnographic Assessment for the Diagnosis of Disorders of Arousal in Children. <i>Neurology</i> , 2021, 96, e121-e130.	1.5	13
74	Social Jetlag Changes During the COVID-19 Pandemic as a Predictor of Insomnia – A Multi-National Survey Study. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1711-1722.	1.4	21
75	Restless legs syndrome. <i>Nature Reviews Disease Primers</i> , 2021, 7, 80.	18.1	81
76	Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure. <i>Journal of Clinical Medicine</i> , 2021, 10, 5387.	1.0	2
77	Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials. <i>CNS Drugs</i> , 2021, 35, 1303-1315.	2.7	4
78	Sleep and daytime problems during the COVID-19 pandemic and effects of coronavirus infection, confinement and financial suffering: a multinational survey using a harmonised questionnaire. <i>BMJ Open</i> , 2021, 11, e050672.	0.8	41
79	Association of Inattention, Hyperactivity, and Hypersomnolence in Two Clinic-Based Adult Cohorts. <i>Journal of Attention Disorders</i> , 2020, 24, 555-564.	1.5	18
80	Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1. <i>Journal of Neurology</i> , 2020, 267, 461-468.	1.8	27
81	Increased blood pressure during the suggested immobilization test in Restless Legs Syndrome. <i>Sleep</i> , 2020, 43, .	0.6	7
82	Genetic, Structural, and Functional Evidence Link <i>TMEM175</i> to Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 139-153.	2.8	65
83	Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1135-1145.	2.5	237
84	Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. <i>Sleep Medicine</i> , 2020, 67, 128-136.	0.8	182
85	Gut microbiota composition is associated with narcolepsy type 1. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	20
86	Reply to Micoulaud-Franchi et Al. Commentary on diagnosis of central disorders of hypersomnolence: From clinic to clinic via ontology and semantic analysis on a bullet point path. <i>Sleep Medicine Reviews</i> , 2020, 52, 101329.	3.8	4
87	Hepcidin and ferritin levels in restless legs syndrome: a case-control study. <i>Scientific Reports</i> , 2020, 10, 11914.	1.6	21
88	Increased Blood Pressure Dipping in Restless Legs Syndrome With Rotigotine: A Randomized Trial. <i>Movement Disorders</i> , 2020, 35, 2164-2173.	2.2	7
89	Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence. <i>Neurology</i> , 2020, 95, e2900-e2911.	1.5	24
90	Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture?. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 1092-1102.	1.9	22

#	ARTICLE	IF	CITATIONS
91	Depression and suicidal thoughts in untreated and treated narcolepsy. <i>Neurology</i> , 2020, 95, e2755-e2768.	1.5	26
92	Reliability of wrist-worn accelerometry devices and algorithms for sleep detection. <i>Alzheimer's and Dementia</i> , 2020, 16, e042808.	0.4	0
93	Disturbed nighttime sleep in children and adults with rhythmic movement disorder. <i>Sleep</i> , 2020, 43, .	0.6	7
94	CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 924-931.	1.7	9
95	Reply to Maski K et al. commentary on diagnosis of central disorders of hypersomnolence: Challenges in defining central disorders of hypersomnolence. <i>Sleep Medicine Reviews</i> , 2020, 52, 101326.	3.8	4
96	<i>GBA</i> variants in REM sleep behavior disorder. <i>Neurology</i> , 2020, 95, e1008-e1016.	1.5	45
97	Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. <i>CNS Drugs</i> , 2020, 34, 773-784.	2.7	10
98	Effects of an individualized exercise training program on severity markers of obstructive sleep apnea syndrome: a randomised controlled trial. <i>Sleep Medicine</i> , 2020, 70, 33-42.	0.8	17
99	Fine-mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 584-598.	2.8	39
100	Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. <i>Annals of Neurology</i> , 2020, 87, 347-356.	2.8	88
101	Variants in the Niemann-Pick type C gene <i>NPC1</i> are not associated with Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 93, 143.e1-143.e4.	1.5	13
102	Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. <i>Sleep Medicine Reviews</i> , 2020, 52, 101306.	3.8	119
103	Analysis of common and rare <i>VPS13C</i> variants in late-onset Parkinson disease. <i>Neurology: Genetics</i> , 2020, 6, 385.	0.9	19
104	<i>SMPD1</i> variants do not have a major role in rapid eye movement sleep behavior disorder. <i>Neurobiology of Aging</i> , 2020, 93, 142.e5-142.e7.	1.5	4
105	Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences. <i>Sleep</i> , 2020, 43, .	0.6	29
106	Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. <i>Neurology</i> , 2020, 94, e2222-e2232.	1.5	62
107	Device agnostic sleep-wake segment classification from wrist-worn accelerometry. , 2020, , .		0
108	Kleine-Levin syndrome is associated with <i>LMOD3</i> variants. <i>Journal of Sleep Research</i> , 2019, 28, e12718.	1.7	12

#	ARTICLE	IF	CITATIONS
109	Impaired glycinergic transmission in hyperekplexia: a model of parasomnia overlap disorder. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1900-1904.	1.7	10
110	Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. <i>Sleep</i> , 2019, 42, .	0.6	213
111	Clinical autonomic dysfunction in narcolepsy type 1. <i>Sleep</i> , 2019, 42, .	0.6	24
112	Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2623-2633.	1.1	19
113	Narcolepsy " clinical spectrum, aetiopathophysiology, diagnosis and treatment. <i>Nature Reviews Neurology</i> , 2019, 15, 519-539.	4.9	364
114	Clinical neurophysiology of CNS hypersomnias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 161, 353-367.	1.0	6
115	Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1. <i>Neurology</i> , 2019, 93, e1034-e1044.	1.5	47
116	Recent advances in treatment for narcolepsy. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641987562.	1.5	64
117	Blood pressure profile and endothelial function in restless legs syndrome. <i>Scientific Reports</i> , 2019, 9, 15933.	1.6	22
118	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	1.4	87
119	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. <i>Frontiers in Neurology</i> , 2019, 10, 989.	1.1	18
120	A randomized study of solriamfetol for excessive sleepiness in narcolepsy. <i>Annals of Neurology</i> , 2019, 85, 359-370.	2.8	274
121	Multiple treatment comparison in narcolepsy: a network meta-analysis" methodological concerns. <i>Sleep</i> , 2019, 42, .	0.6	1
122	Measurement of symptoms in idiopathic hypersomnia. <i>Neurology</i> , 2019, 92, e1754-e1762.	1.5	47
123	Shared T cell receptor chains in blood memory CD4+ T cells of narcolepsy type 1 patients. <i>Journal of Autoimmunity</i> , 2019, 100, 1-6.	3.0	7
124	SMPD1 mutations, activity, and $\alpha$ -synuclein accumulation in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 526-535.	2.2	81
125	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. <i>Brain</i> , 2019, 142, 744-759.	3.7	636
126	Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder. <i>Sleep</i> , 2019, 42, .	0.6	23



#	ARTICLE	IF	CITATIONS
127	Disorders of Arousal in adults: new diagnostic tools for clinical practice. <i>Sleep Science and Practice</i> , 2019, 3, .	0.6	21
128	Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy. <i>Anesthesia and Analgesia</i> , 2019, 129, 204-211.	1.1	4
129	Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise. <i>Scientific Reports</i> , 2019, 9, 18432.	1.6	14
130	French Language Online Cognitive Behavioral Therapy for Insomnia Disorder: A Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2019, 10, 1273.	1.1	7
131	Common and rare GCH1 variants are associated with Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 73, 231.e1-231.e6.	1.5	20
132	Impaired histaminergic neurotransmission in children with narcolepsy type 1. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 386-395.	1.9	21
133	Histamine: neural circuits and new medications. <i>Sleep</i> , 2019, 42, .	0.6	71
134	Validation of the French Version of the Weiss Functional Impairment Rating Scale—Self-Report in a Large Cohort of Adult Patients With ADHD. <i>Journal of Attention Disorders</i> , 2019, 23, 1148-1159.	1.5	7
135	Exploration of cardiac sympathetic adrenergic nerve activity in narcolepsy. <i>Clinical Neurophysiology</i> , 2019, 130, 412-418.	0.7	13
136	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. <i>Annals of Neurology</i> , 2019, 85, 74-83.	2.8	18
137	Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia. <i>Sleep Medicine</i> , 2019, 55, 1-5.	0.8	22
138	Persistence of deep-tendon reflexes during partial cataplexy. <i>Sleep Medicine</i> , 2018, 45, 80-82.	0.8	10
139	Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 687-696.	1.0	17
140	Kinesthetic stimulation for obstructive sleep apnea syndrome: An on-off-proof of concept trial. <i>Scientific Reports</i> , 2018, 8, 3092.	1.6	5
141	Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. <i>Neurology</i> , 2018, 90, e479-e491.	1.5	40
142	TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson's Disease with Opposite Effects. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 341-345.	1.1	11
143	Association between serum hepcidin level and restless legs syndrome. <i>Movement Disorders</i> , 2018, 33, 618-627.	2.2	25
144	The distinguishing motor features of cataplexy: a study from video-recorded attacks. <i>Sleep</i> , 2018, 41, .	0.6	26

#	ARTICLE	IF	CITATIONS
145	Diagnostic criteria for disorders of arousal: A video-polysomnographic assessment. <i>Annals of Neurology</i> , 2018, 83, 341-351.	2.8	66
146	Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. <i>Journal of Neuroimmunology</i> , 2018, 315, 28-32.	1.1	17
147	Association study of essential tremor genetic loci in Parkinson's disease. <i>Neurobiology of Aging</i> , 2018, 66, 178.e13-178.e15.	1.5	9
148	A provisional tool for the measurement of sleep satisfaction. <i>Sleep Health</i> , 2018, 4, 6-12.	1.3	17
149	Update on treatment for idiopathic hypersomnia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 187-192.	1.9	26
150	Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol. <i>Annals of Neurology</i> , 2018, 83, 235-247.	2.8	62
151	LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 98-101.	1.1	25
152	The clinical spectrum of childhood narcolepsy. <i>Sleep Medicine Reviews</i> , 2018, 38, 70-85.	3.8	86
153	Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. <i>Nature Communications</i> , 2018, 9, 5229.	5.8	194
154	POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. <i>Clinical and Translational Allergy</i> , 2018, 8, 36.	1.4	70
155	REM sleep behaviour disorder. <i>Nature Reviews Disease Primers</i> , 2018, 4, 19.	18.1	290
156	Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 483-494.	2.7	78
157	Full sequencing and haplotype analysis of <i>MAPT</i> in Parkinson's disease and rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2018, 33, 1016-1020.	2.2	31
158	NREM sleep parasomnias as disorders of sleep-state dissociation. <i>Nature Reviews Neurology</i> , 2018, 14, 470-481.	4.9	132
159	Sequencing of the GBA coactivator, Saposin C, in Parkinson disease. <i>Neurobiology of Aging</i> , 2018, 72, 187.e1-187.e3.	1.5	16
160	Circulating follicular helper T cells exhibit reduced ICOS expression and impaired function in narcolepsy type 1 patients. <i>Journal of Autoimmunity</i> , 2018, 94, 134-142.	3.0	8
161	Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning. <i>Scientific Reports</i> , 2018, 8, 10628.	1.6	36
162	Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder. <i>Scientific Reports</i> , 2018, 8, 7304.	1.6	22

#	ARTICLE	IF	CITATIONS
163	Circadian Rhythm Disturbances in the Blind. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 65.	2.0	28
164	Editorial. <i>Revue Neurologique</i> , 2017, 173, 6-7.	0.6	0
165	National Sleep Foundation's sleep quality recommendations: first report. <i>Sleep Health</i> , 2017, 3, 6-19.	1.3	729
166	Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 200-207.	4.9	306
167	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. <i>Neurobiology of Aging</i> , 2017, 53, 59-66.	1.5	76
168	Hypersomnolence, Hypersomnia, and Mood Disorders. <i>Current Psychiatry Reports</i> , 2017, 19, 13.	2.1	61
169	RIC3 variants are not associated with Parkinson's disease in French-Canadians and French. <i>Neurobiology of Aging</i> , 2017, 53, 194.e9-194.e11.	1.5	5
170	Narcolepsy. <i>Nature Reviews Disease Primers</i> , 2017, 3, 16100.	18.1	185
171	Measurement of narcolepsy symptoms. <i>Neurology</i> , 2017, 88, 1358-1365.	1.5	74
172	Is the Muscle the Only Potential Target of Desipramine in Obstructive Sleep Apnea Syndrome?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1677-1678.	2.5	4
173	Effects of 1â€‘month withdrawal of ventilatory support in hypercapnic myotonic dystrophy type 1. <i>Respirology</i> , 2017, 22, 1416-1422.	1.3	25
174	Author response: Comorbidity between central disorders of hypersomnolence and immune-based disorders. <i>Neurology</i> , 2017, 88, 1777-1777.	1.5	0
175	Rare missense mutations in P2RY11 in narcolepsy with cataplexy. <i>Brain</i> , 2017, 140, 1657-1668.	3.7	27
176	MEIS1 variant as a determinant of autonomic imbalance in Restless Legs Syndrome. <i>Scientific Reports</i> , 2017, 7, 46620.	1.6	22
177	Reply to â€œRigor, reproducibility and in vitro CSF assays: The devil in the detailsâ€‘. <i>Annals of Neurology</i> , 2017, 81, 907-910.	2.8	0
178	Depression and Hypersomnia. <i>Sleep Medicine Clinics</i> , 2017, 12, 395-405.	1.2	47
179	Low cerebrospinal fluid hypocretin levels during sudden infant death syndrome (SIDS) risk period. <i>Sleep Medicine</i> , 2017, 33, 57-60.	0.8	5
180	Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2017, 140, e32-e32.	3.7	5

#	ARTICLE	IF	CITATIONS
181	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 898-907.	4.9	191
182	Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. <i>CNS Drugs</i> , 2017, 31, 821-834.	2.7	29
183	Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study. <i>Scientific Reports</i> , 2017, 7, 1372.	1.6	64
184	Is adult-onset attention deficit/hyperactivity disorder frequent in clinical practice?. <i>Psychiatry Research</i> , 2017, 257, 238-241.	1.7	9
185	Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. <i>Sleep Medicine</i> , 2017, 40, 53-57.	0.8	24
186	French consensus. Idiopathic hypersomnia: Investigations and follow-up. <i>Revue Neurologique</i> , 2017, 173, 32-37.	0.6	11
187	Comorbidity between central disorders of hypersomnolence and immune-based disorders. <i>Neurology</i> , 2017, 88, 93-100.	1.5	50
188	The dementia-associated APOE $\epsilon$ 4 allele is not associated with rapid eye movement sleep behavior disorder. <i>Neurobiology of Aging</i> , 2017, 49, 218.e13-218.e15.	1.5	25
189	Vitamin D deficiency in type 1 narcolepsy: a reappraisal. <i>Sleep Medicine</i> , 2017, 29, 1-6.	0.8	12
190	French consensus. Hypersomnolence: Evaluation and diagnosis. <i>Revue Neurologique</i> , 2017, 173, 19-24.	0.6	12
191	French consensus. Management of patients with hypersomnia: Which strategy?. <i>Revue Neurologique</i> , 2017, 173, 8-18.	0.6	35
192	Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. <i>Journal of Sleep Research</i> , 2017, 26, 407-414.	1.7	43
193	Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. <i>Sleep</i> , 2017, 40, .	0.6	35
194	Test-Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence. <i>Sleep</i> , 2017, 40, .	0.6	94
195	Idiopathic Hypersomnia. , 2017, , 883-891.e4.		2
196	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 312.	1.7	26
197	To Increase Our Knowledge on Sleep, Sleep Disorders, and Chronobiology in the Neuroscience Field during the Next Decade. <i>Frontiers in Neurology</i> , 2017, 8, 16.	1.1	1
198	[ $^{18}$ F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. <i>Frontiers in Neurology</i> , 2017, 8, 350.	1.1	26

#	ARTICLE	IF	CITATIONS
199	Restless legs syndrome and cardiovascular diseases: A case-control study. PLoS ONE, 2017, 12, e0176552.	1.1	29
200	Narcolepsy and Other Central Hypersomnias. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 989-1004.	0.4	17
201	Genetics of Sleep and Sleep Disorders. , 2017, , 523-537.		0
202	Is Restless Legs Syndrome Involved in Ambulation Related to Sleepwalking?. Sleep, 2016, 39, 955-956.	0.6	5
203	The European Narcolepsy Network (<scp>EU</scp>â€‹<scp>NN</scp>) database. Journal of Sleep Research, 2016, 25, 356-364.	1.7	47
204	Absence of Î³-aminobutyric acidâ€œ receptor potentiation in central hypersomnolence disorders. Annals of Neurology, 2016, 80, 259-268.	2.8	48
205	Excessive daytime sleepiness and antipathogen drug consumption in the elderly: a test of the immune theory of sleep. Scientific Reports, 2016, 6, 23574.	1.6	2
206	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports, 2016, 6, 25162.	1.6	36
207	Time to find a biomarker in Kleineâ€œLevin Syndrome. Sleep Medicine, 2016, 21, 177.	0.8	6
208	The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder. Neurobiology of Aging, 2016, 43, 180.e7-180.e13.	1.5	12
209	Treatment Options for Narcolepsy. CNS Drugs, 2016, 30, 369-379.	2.7	83
210	Management of Narcolepsy. Current Treatment Options in Neurology, 2016, 18, 43.	0.7	44
211	Risk Factor Profile in Parkinsonâ€™s Disease Subtype with REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2016, 6, 231-237.	1.5	21
212	CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10956-10961.	3.3	106
213	High-dimensional single-cell analysis reveals the immune signature of narcolepsy. Journal of Experimental Medicine, 2016, 213, 2621-2633.	4.2	106
214	Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. Sleep, 2016, 39, 573-580.	0.6	34
215	Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. Sleep, 2016, 39, 581-587.	0.6	66
216	Impact of Astroglial Connexins on Modafinil Pharmacological Properties. Sleep, 2016, 39, 1283-1292.	0.6	50

#	ARTICLE	IF	CITATIONS
217	Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 45, 212.e13-212.e17.	1.5	38
218	Impact of sleep disturbances on kidney function decline in the elderly. <i>European Respiratory Journal</i> , 2016, 47, 860-868.	3.1	18
219	Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 68, 434-443.	2.1	33
220	From state dissociation to status dissociatus. <i>Sleep Medicine Reviews</i> , 2016, 28, 5-17.	3.8	56
221	Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac death. <i>ELife</i> , 2016, 5, .	2.8	27
222	Narcolepsie : Lien avec l'™infection et la vaccination antigrippale H1N1 ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2016, 200, 1191-1201.	0.0	0
223	Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. <i>Sleep</i> , 2015, 38, 1051-1058.	0.6	49
224	Pain in Sleepwalking: A Clinical Enigma. <i>Sleep</i> , 2015, 38, 1693-1698.	0.6	37
225	Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study. <i>Sleep</i> , 2015, 38, 1285-1295.	0.6	120
226	GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 941-945.	1.7	117
227	Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2015, 138, e390-e390.	3.7	7
228	Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleineâ€“Levin syndrome. <i>Sleep Medicine</i> , 2015, 16, 194-196.	0.8	28
229	HLA-DPB1 and HLA Class I Confer Risk of and Protection from Narcolepsy. <i>American Journal of Human Genetics</i> , 2015, 96, 136-146.	2.6	125
230	Clinical and practical considerations in the pharmacologic management of narcolepsy. <i>Sleep Medicine</i> , 2015, 16, 9-18.	0.8	106
231	<scp>K</scp>leineâ€“<scp>L</scp>evin syndrome in 120 patients: Differential diagnosis and long episodes. <i>Annals of Neurology</i> , 2015, 77, 529-540.	2.8	66
232	Interactions of the histamine and hypocretin systems in CNS disorders. <i>Nature Reviews Neurology</i> , 2015, 11, 401-413.	4.9	80
233	A multidimensional approach of impulsivity in adult attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2015, 227, 290-295.	1.7	44
234	Sleep Complaints and Metabolic Syndrome in an Elderly Population: The Three-City Study. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 818-828.	0.6	31

#	ARTICLE	IF	CITATIONS
235	Impact of cytokine in type 1 narcolepsy: Role of pandemic H1N1 vaccination ?. Journal of Autoimmunity, 2015, 60, 20-31.	3.0	44
236	Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Annals of Neurology, 2015, 77, 830-839.	2.8	248
237	Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. Sleep Medicine Reviews, 2015, 22, 47-53.	3.8	66
238	Car Crashes and Central Disorders of Hypersomnolence: A French Study. PLoS ONE, 2015, 10, e0129386.	1.1	62
239	Widespread Hypermetabolism in Symptomatic and Asymptomatic Episodes in Kleine-Levin Syndrome. PLoS ONE, 2014, 9, e93813.	1.1	35
240	Daytime Sleepiness in Parkinson's Disease: A Reappraisal. PLoS ONE, 2014, 9, e107278.	1.1	64
241	Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index. PLoS Genetics, 2014, 10, e1004508.	1.5	80
242	Challenges in Diagnosing Narcolepsy without Cataplexy: A Consensus Statement. Sleep, 2014, 37, 1035-1042.	0.6	145
243	Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy. Neurology, 2014, 83, 1080-1086.	1.5	47
244	Quality of Life in Children with Narcolepsy. CNS Neuroscience and Therapeutics, 2014, 20, 763-771.	1.9	63
245	C9orf72 Repeat Expansions in Rapid Eye Movement Sleep Behaviour Disorder. Canadian Journal of Neurological Sciences, 2014, 41, 759-762.	0.3	18
246	Objective daytime sleepiness in patients with somnambulism or sleep terrors. Neurology, 2014, 83, 2070-2076.	1.5	40
247	Hypertension and sleep: Overview of a tight relationship. Sleep Medicine Reviews, 2014, 18, 509-519.	3.8	181
248	Comorbidity and medication in REM sleep behavior disorder. Neurology, 2014, 82, 1076-1079.	1.5	90
249	Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2014, 137, 3122-3128.	3.7	134
250	Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. Journal of Neurology, 2014, 261, 1112-1118.	1.8	90
251	Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1411-1414.	1.1	22
252	From Phenomenology to Neurophysiological Understanding of Hallucinations in Children and Adolescents. Schizophrenia Bulletin, 2014, 40, S221-S232.	2.3	71

#	ARTICLE	IF	CITATIONS
253	Depressive feelings in children with narcolepsy. <i>Sleep Medicine</i> , 2014, 15, 309-314.	0.8	61
254	Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: A case-control study. <i>Brain, Behavior, and Immunity</i> , 2014, 37, 260-266.	2.0	36
255	Cataplexy's clinical aspects, pathophysiology and management strategy. <i>Nature Reviews Neurology</i> , 2014, 10, 386-395.	4.9	153
256	Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy. <i>Sleep Medicine</i> , 2014, 15, 1046-1054.	0.8	32
257	DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe. <i>Sleep</i> , 2014, 37, 19-25.	0.6	164
258	Hypersomnia and depressive symptoms: methodological and clinical aspects. <i>BMC Medicine</i> , 2013, 11, 78.	2.3	106
259	Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. <i>Journal of Sleep Research</i> , 2013, 22, 482-495.	1.7	182
260	Daytime Sleepiness and Myotonic Dystrophy. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 340.	2.0	67
261	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. <i>Sleep Medicine</i> , 2013, 14, 775-781.	0.8	94
262	Daytime somnolence in adult sleepwalkers. <i>Sleep Medicine</i> , 2013, 14, 1187-1191.	0.8	29
263	Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2013, 12, 1068-1075.	4.9	301
264	Hypnotics and mortality in an elderly general population: a 12-year prospective study. <i>BMC Medicine</i> , 2013, 11, 212.	2.3	64
265	Management of narcolepsy during pregnancy. <i>Sleep Medicine</i> , 2013, 14, 367-376.	0.8	58
266	Decision making and addictive behaviors in narcolepsy with cataplexy. <i>Sleep and Biological Rhythms</i> , 2013, 11, 62-64.	0.5	0
267	Pharmacotherapy options for cataplexy. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 895-903.	0.9	22
268	Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart review. <i>Sleep Medicine</i> , 2013, 14, 30-36.	0.8	76
269	Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. <i>Vaccine</i> , 2013, 31, 994-1007.	1.7	58
270	Impact of Obesity in Children with Narcolepsy. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 521-528.	1.9	74



#	ARTICLE	IF	CITATIONS
271	Treatment options in narcolepsy. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 987-999.	0.5	0
272	Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. <i>Brain</i> , 2013, 136, 2486-2496.	3.7	203
273	Clinical and polysomnographic course of childhood narcolepsy with cataplexy. <i>Brain</i> , 2013, 136, 3787-3795.	3.7	113
274	ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy. <i>PLoS Genetics</i> , 2013, 9, e1003270.	1.5	206
275	Family history of idiopathic REM behavior disorder. <i>Neurology</i> , 2013, 80, 2233-2235.	1.5	54
276	Restless legs syndrome. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 594-600.	1.2	97
277	Hypothalamic Immunopathology in Anti-Ma <sup>α</sup> -Associated Diencephalitis With Narcolepsy-Cataplexy. <i>JAMA Neurology</i> , 2013, 70, 1305-10.	4.5	73
278	Facial expression recognition and emotional regulation in narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2013, 22, 170-177.	1.7	9
279	Excessive sleep duration and quality of life. <i>Annals of Neurology</i> , 2013, 73, 785-794.	2.8	120
280	Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. <i>Journal of Sleep Research</i> , 2013, 22, 496-512.	1.7	54
281	Functional Impairment in Adult Sleepwalkers: A Case-Control Study. <i>Sleep</i> , 2013, 36, 345-351.	0.6	101
282	Effect of Psychostimulants on Impulsivity and Risk Taking in Narcolepsy with Cataplexy. <i>Sleep</i> , 2013, 36, 1335-1340.	0.6	26
283	Decision-Making, Reward-Seeking Behaviors and Dopamine Agonist Therapy in Restless Legs Syndrome. <i>Sleep</i> , 2013, 36, 1501-1507.	0.6	55
284	Disrupted Nighttime Sleep in Narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2013, 09, 955-965.	1.4	156
285	Insomnia, Daytime Sleepiness and Cardio-Cerebrovascular Diseases in the Elderly: A 6-Year Prospective Study. <i>PLoS ONE</i> , 2013, 8, e56048.	1.1	49
286	Differences in Brain Morphological Findings between Narcolepsy with and without Cataplexy. <i>PLoS ONE</i> , 2013, 8, e81059.	1.1	25
287	Conflicts of Interest—Reply. <i>Archives of General Psychiatry</i> , 2012, 69, 1181.	13.8	0
288	Operational Definitions and Algorithms for Excessive Sleepiness in the General Population. <i>Archives of General Psychiatry</i> , 2012, 69, 71.	13.8	100

#	ARTICLE	IF	CITATIONS
289	Excessive Sleepiness is Predictive of Cognitive Decline in the Elderly. <i>Sleep</i> , 2012, 35, 1201-1207.	0.6	178
290	Trajectories of Sleep Complaints From Early Midlife to Old Age: Longitudinal Modeling Study. <i>Sleep</i> , 2012, 35, 1559-68.	0.6	15
291	Heritability in chronic insomnia. <i>Sleep Medicine</i> , 2012, 13, 969-970.	0.8	3
292	Rhythmic movement disorder associated with restless legs syndrome. <i>Sleep Medicine</i> , 2012, 13, 1324-1325.	0.8	7
293	Age-related changes in sleep in inbred mice are genotype dependent. <i>Neurobiology of Aging</i> , 2012, 33, 195.e13-195.e26.	1.5	77
294	Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials. <i>Sleep Medicine Reviews</i> , 2012, 16, 431-443.	3.8	111
295	Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. <i>Sleep Medicine Reviews</i> , 2012, 16, 539-545.	3.8	72
296	The burden of narcolepsy with cataplexy: How disease history and clinical features influence socio-economic outcomes. <i>Sleep Medicine</i> , 2012, 13, 1293-1300.	0.8	69
297	Executive Control of Attention in Narcolepsy. <i>PLoS ONE</i> , 2012, 7, e33525.	1.1	59
298	Predictors of Hypocretin (Orexin) Deficiency in Narcolepsy Without Cataplexy. <i>Sleep</i> , 2012, 35, 1247-1255.	0.6	182
299	Normal Cerebrospinal Fluid Histamine and tele-Methylhistamine Levels in Hypersomnia Conditions. <i>Sleep</i> , 2012, 35, 1359-1366.	0.6	83
300	Altered Sleep-Related Blood Pressure Profile in Hypocretin-Deficient Narcoleptic Patients. <i>Sleep</i> , 2012, 35, 453-454.	0.6	4
301	Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 743-749.	2.2	37
302	A singleâ€question screen for rapid eye movement sleep behavior disorder: A multicenter validation study. <i>Movement Disorders</i> , 2012, 27, 913-916.	2.2	311
303	Excessive daytime sleepiness and vascular events: The Three City Study. <i>Annals of Neurology</i> , 2012, 71, 661-667.	2.8	71
304	Periodic leg movements during sleep in narcoleptic patients with or without restless legs syndrome. <i>Journal of Sleep Research</i> , 2012, 21, 155-162.	1.7	39
305	Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy. <i>PLoS ONE</i> , 2012, 7, e38977.	1.1	85
306	Ventilatory disorders and facial growth: Benefits of early genioplasty. <i>International Orthodontics</i> , 2011, 9, 20-41.	0.6	7

#	ARTICLE	IF	CITATIONS
307	Insomnia Symptoms in Older Adults: Associated Factors and Gender Differences. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 88-97.	0.6	214
308	Recurrent hypersomnia: A review of 339 cases. <i>Sleep Medicine Reviews</i> , 2011, 15, 247-257.	3.8	116
309	Insomnia in central neurologic diseases – Occurrence and management. <i>Sleep Medicine Reviews</i> , 2011, 15, 369-378.	3.8	91
310	High pain frequency in narcolepsy with cataplexy. <i>Sleep Medicine</i> , 2011, 12, 572-577.	0.8	37
311	Increased perfusion in supplementary motor area during a REM sleep behaviour episode. <i>Sleep Medicine</i> , 2011, 12, 531-532.	0.8	40
312	Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. <i>Sleep Medicine</i> , 2011, 12, 550-556.	0.8	70
313	Melanin concentrating hormone in central hypersomnia. <i>Sleep Medicine</i> , 2011, 12, 768-772.	0.8	23
314	Daytime Sleepiness and REM Sleep Characteristics in Myotonic Dystrophy: A Case-Control Study. <i>Sleep</i> , 2011, 34, 165-170.	0.6	82
315	Comments on the Letter to the Editor by Ferri et al. on Autonomic Response to Periodic Leg Movements in Sleep in Narcolepsy-Cataplexy. <i>Sleep</i> , 2011, 34, 411-412.	0.6	0
316	Comment on the Letter to the Editor By Dr. Marcus on the Association between Narcolepsy and H1N1 Exposure. <i>Sleep</i> , 2011, 34, 689-690.	0.6	2
317	Idiopathic Hypersomnia. , 2011, , 969-979.		4
318	Autonomic Response to Periodic Leg Movements during Sleep in Narcolepsy-Cataplexy. <i>Sleep</i> , 2011, 34, 219-223.	0.6	44
319	Decision Making in Narcolepsy with Cataplexy. <i>Sleep</i> , 2011, 34, 99-104.	0.6	58
320	Low Vitamin D in Narcolepsy with Cataplexy. <i>PLoS ONE</i> , 2011, 6, e20433.	1.1	30
321	Current and future therapeutic approaches in narcolepsy. <i>Future Neurology</i> , 2011, 6, 771-782.	0.9	3
322	Insomnia and Daytime Sleepiness Are Risk Factors for Depressive Symptoms in the Elderly. <i>Sleep</i> , 2011, 34, 1103-1110.	0.6	226
323	Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization. <i>Analytical Biochemistry</i> , 2011, 409, 28-36.	1.1	39
324	The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. <i>Brain</i> , 2011, 134, 856-862.	3.7	66

#	ARTICLE	IF	CITATIONS
325	Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. <i>Brain</i> , 2011, 134, 3480-3492.	3.7	159
326	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. <i>PLoS Genetics</i> , 2011, 7, e1002171.	1.5	163
327	Aspectos genéticos y trastornos del sueño en el ser humano y en los animales de experimentación. , 2011, , 295-306.		0
328	Parasomnias in Narcolepsy with Cataplexy. , 2011, , 291-299.		1
329	Post-H1N1 Narcolepsy-Cataplexy. <i>Sleep</i> , 2010, 33, 1428-1430.	0.6	187
330	Restless Legs Syndrome is Frequent in Narcolepsy with Cataplexy Patients. <i>Sleep</i> , 2010, 33, 689-694.	0.6	62
331	Sleep and dementia. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 201-202.	1.5	12
332	Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2010, 25, 2044-2051.	2.2	253
333	Decision making in restless legs syndrome. <i>Movement Disorders</i> , 2010, 25, 2634-2640.	2.2	26
334	Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. <i>Journal of Sleep Research</i> , 2010, 19, 620-623.	1.7	54
335	Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. <i>Nature Genetics</i> , 2010, 42, 786-789.	9.4	170
336	Sodium oxybate is an effective and safe treatment for narcolepsy. <i>Sleep Medicine</i> , 2010, 11, 105-106.	0.8	29
337	Olfactory dysfunction in narcolepsy with cataplexy. <i>Sleep Medicine</i> , 2010, 11, 876-881.	0.8	23
338	A brain PET study in patients with narcolepsy-cataplexy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 344-348.	0.9	55
339	Impact of genioplasty on mandibular growth during puberty. <i>International Orthodontics</i> , 2010, 8, 342-359.	0.6	16
340	Diurnal and Nocturnal Sleep in Narcolepsy with Cataplexy. , 2010, , 77-85.		2
341	Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. <i>Journal of Clinical Investigation</i> , 2010, 120, 713-719.	3.9	263
342	Increased Immune Complexes of Hypocretin Autoantibodies in Narcolepsy. <i>PLoS ONE</i> , 2010, 5, e13320.	1.1	33

#	ARTICLE	IF	CITATIONS
343	REM Sleep Behavior Disorder in Narcolepsy with Cataplexy. , 2010, , 99-103.		0
344	Excessive Daytime Sleepiness Is an Independent Risk Indicator for Cardiovascular Mortality in Community-Dwelling Elderly. <i>Stroke</i> , 2009, 40, 1219-1224.	1.0	152
345	Pressure Reduction During Exhalation in Sleep Apnea Patients Treated by Continuous Positive Airway Pressure. <i>Chest</i> , 2009, 136, 490-497.	0.4	38
346	Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. <i>Neurology</i> , 2009, 73, 1333-1334.	1.5	89
347	Psychological health in central hypersomnias: the French Harmony study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 636-641.	0.9	148
348	Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split?. <i>Neuromuscular Disorders</i> , 2009, 19, 397-402.	0.3	64
349	Human and Animal Genetics of Sleep and Sleep Disorders. , 2009, , 295-306.		1
350	An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin <sup>+/+</sup> mice and patients. <i>Neurobiology of Disease</i> , 2008, 30, 74-83.	2.1	254
351	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2008, 338, 75-78.	0.6	11
352	The Genetic Basis of Sleep Disorders. <i>Current Pharmaceutical Design</i> , 2008, 14, 3386-3395.	0.9	23
353	Hypocretin and Human African Trypanosomiasis. <i>Sleep</i> , 2008, 31, 348-354.	0.6	25
354	Diagnostic Algorithm for Hypersomnias. , 2008, , 277-297.		0
355	REVERSAL OF SYMPTOMATIC TUMORAL NARCOLEPSY, WITH NORMALIZATION OF CSF HYPOCRETIN LEVEL. <i>Neurology</i> , 2007, 69, 1300-1301.	1.5	18
356	REM Sleep Characteristics in Narcolepsy and REM Sleep Behavior Disorder. <i>Sleep</i> , 2007, 30, 844-849.	0.6	169
357	Family History of Insomnia in a Population-Based Sample. <i>Sleep</i> , 2007, 30, 1739-1745.	0.6	93
358	Restless legs syndrome in narcolepsy: A side effect of sodium oxybate?. <i>Sleep Medicine</i> , 2007, 8, 181-183.	0.8	28
359	Narcolepsy and familial advanced sleep-phase syndrome: molecular genetics of sleep disorders. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 222-227.	1.5	21
360	Narcolepsy with cataplexy. <i>Lancet, The</i> , 2007, 369, 499-511.	6.3	647

#	ARTICLE	IF	CITATIONS
361	Insomnia in patients with neurodegenerative conditions. <i>Sleep Medicine</i> , 2007, 8, S27-S34.	0.8	152
362	A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. <i>Movement Disorders</i> , 2007, 22, 1567-1572.	2.2	106
363	Periodic leg movements during sleep and wakefulness in narcolepsy. <i>Journal of Sleep Research</i> , 2007, 16, 333-339.	1.7	102
364	Determinants of excessive daytime sleepiness in a French community-dwelling elderly population. <i>Journal of Sleep Research</i> , 2007, 16, 364-371.	1.7	69
365	Narcolepsy with Cataplexy: Hypocretin and Immunological Aspects. , 2007, , 337-352.		0
366	Molecular genetics and treatment of narcolepsy. <i>Annals of Medicine</i> , 2006, 38, 252-262.	1.5	43
367	Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. <i>Sleep Medicine</i> , 2006, 7, 649-651.	0.8	31
368	Differential diagnosis in hypersomnia. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 156-162.	2.0	49
369	Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. <i>Annals of Neurology</i> , 2006, 60, 153-153.	2.8	58
370	No effect on cognitive function from daily mobile phone use. <i>Bioelectromagnetics</i> , 2005, 26, 102-108.	0.9	64
371	Hypocretin in Neuropsychiatric Disorders. , 2005, , 263-277.		0
372	Genes for normal sleep and sleep disorders. <i>Annals of Medicine</i> , 2005, 37, 580-589.	1.5	62
373	Retinoic Acid Signaling Affects Cortical Synchrony During Sleep. <i>Science</i> , 2005, 310, 111-113.	6.0	102
374	Family studies in insomnia. <i>Journal of Psychosomatic Research</i> , 2005, 58, 271-278.	1.2	111
375	Hypersomnia. <i>Dialogues in Clinical Neuroscience</i> , 2005, 7, 347-356.	1.8	32
376	Dissociation in circadian rhythms in a pseudohypersomnia form of fatal familial insomnia. <i>Neurology</i> , 2004, 63, 2416-2418.	1.5	21
377	Effect of age on MSLT results in patients with narcolepsy-cataplexy. <i>Neurology</i> , 2004, 62, 46-50.	1.5	127
378	Normal CSF Hypocretin-1 (Orexin A) Levels in Dementia with Lewy Bodies Associated with Excessive Daytime Sleepiness. <i>European Neurology</i> , 2004, 52, 73-76.	0.6	82

#	ARTICLE	IF	CITATIONS
379	A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. <i>Neurology</i> , 2004, 62, 2137-2138.	1.5	55
380	Effect of cognitive behavioural therapy for insomnia on sleep architecture and sleep EEG power spectra in psychophysiological insomnia. <i>Journal of Sleep Research</i> , 2004, 13, 385-393.	1.7	107
381	Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds. <i>Pflugers Archiv European Journal of Physiology</i> , 2004, 447, 915-921.	1.3	49
382	A narcolepsy susceptibility locus maps to a 5Mb region of chromosome 21q. <i>Annals of Neurology</i> , 2004, 56, 382-388.	2.8	54
383	Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. <i>Annals of Neurology</i> , 2004, 56, 905-908.	2.8	152
384	Clinical aspects and pathophysiology of narcolepsy. <i>Clinical Neurophysiology</i> , 2003, 114, 2000-2017.	0.7	122
385	Energy cost of walking and gait instability in healthy 65- and 80-yr-olds. <i>Journal of Applied Physiology</i> , 2003, 95, 2248-2256.	1.2	193
386	CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1667-1673.	0.9	274
387	Pharmacogenomics in the treatment of narcolepsy. <i>Pharmacogenomics</i> , 2003, 4, 23-33.	0.6	22
388	Month of Birth as a Risk Factor for Narcolepsy. <i>Sleep</i> , 2003, 26, 663-665.	0.6	64
389	Arousal Reactions in Sleepwalking and Night Terrors in Adults: The Role of Respiratory Events. <i>Sleep</i> , 2002, 25, 32-36.	0.6	99
390	Severity of Narcolepsy Among French of Different Ethnic Origins (South of France and Martinique). <i>Sleep</i> , 2002, 25, 50-55.	0.6	22
391	Arousal reactions in sleepwalking and night terrors in adults: the role of respiratory events. <i>Sleep</i> , 2002, 25, 871-5.	0.6	22
392	Age at onset of narcolepsy in two large populations of patients in France and Quebec. <i>Neurology</i> , 2001, 57, 2029-2033.	1.5	369
393	Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. <i>Nature and Science of Sleep</i> , 0, Volume 14, 1031-1047.	1.4	18